Updated: January 20, 2026
How to Help Your Patients Find Amifampridine (Firdapse) in Stock: A Provider's Guide
Author
Peter Daggett

- Step 1: Confirm the Diagnosis Comprehensively Before Prescribing
- Step 2: Engage Catalyst Pathways at the Time of Prescribing
- Step 3: Route the Prescription to the Correct Specialty Pharmacy
- Step 4: Submit a Strong Prior Authorization Letter
- Step 5: Request Expedited Review When Clinically Appropriate
- Step 6: Manage Reauthorization Proactively
- How medfinder Can Help Your Patients
Overview
A practical guide for neurologists and prescribers on navigating the specialty pharmacy system to help LEMS patients access amifampridine (Firdapse) quickly in 2026.
Is Amifampridine in stock near you?
Medfinder checks real pharmacy inventory — start a search and we'll find Amifampridine near you.
For clinicians treating Lambert-Eaton Myasthenic Syndrome (LEMS), getting patients started on amifampridine (Firdapse) requires more than writing a prescription. The drug is dispensed exclusively through specialty pharmacies, subject to mandatory prior authorization, and supported by a manufacturer patient assistance program that your office must help initiate. This guide walks through the practical steps you can take to minimize the time between diagnosis and first dose.
Step 1: Confirm the Diagnosis Comprehensively Before Prescribing
Every payer will require specific diagnostic evidence before approving amifampridine. By ensuring your clinical workup is complete before prescribing, you prevent delays caused by incomplete documentation:
EMG/NCS: Document post-exercise facilitation and CMAP increment on repetitive nerve stimulation at 50 Hz (>60% increment is the typical threshold)
VGCC antibodies: Send voltage-gated calcium channel antibody panel (positive in ~85% of LEMS cases)
Cancer screening: CT chest and PET scan for small-cell lung cancer, which accounts for ~50–60% of LEMS cases
Seizure history: Confirm the patient has no seizure history (amifampridine is contraindicated)
Check live stock now.
Step 2: Engage Catalyst Pathways at the Time of Prescribing
Do not wait until after prescribing to contact Catalyst Pathways. Initiate enrollment at the same time you write the prescription. Catalyst Pathways (1-833-422-8259) will:
Verify the patient's insurance coverage and identify the in-network specialty pharmacy
Coordinate prior authorization submission on your behalf
Enroll the patient in the copay assistance program ($0/month for eligible commercially insured patients)
Provide free bridge medication if coverage is pending
Step 3: Route the Prescription to the Correct Specialty Pharmacy
Do not send the prescription to a retail pharmacy — they cannot fill it. Firdapse requires a specialty pharmacy that is in-network with the patient's insurance. Catalyst Pathways will identify the correct pharmacy. Common specialty pharmacy networks that dispense amifampridine include CVS Specialty, Walgreens Specialty, Accredo (Express Scripts), Optum Specialty, and Biologics by McKesson. Send the prescription directly by electronic prescribing or fax.
Step 4: Submit a Strong Prior Authorization Letter
Your PA letter is the most important document in the access process. A well-written letter significantly reduces the chances of denial and saves time. Structure your letter to address each of these points:
Patient diagnosis — ICD-10 code G70.80 (Other myasthenia gravis) or G70.89 (Other specified myoneural disorders) with specific LEMS clinical findings
Electrodiagnostic evidence — cite specific EMG values (CMAP amplitudes at rest and post-exercise, percent increment at 50 Hz)
Antibody results — VGCC antibody titer value and reference lab
Functional impairment — use validated tools (QMG score, Timed 25-Foot Walk, dynamometry) to document severity
Treatment rationale — reference FDA labeling: Firdapse is indicated for LEMS in patients 6 years and older (NDA 208078, updated May 2024 with 100 mg/day maximum)
Lack of alternatives — state that no FDA-approved generic exists and that Ruzurgi's approval was withdrawn in 2022
Step 5: Request Expedited Review When Clinically Appropriate
Standard PA decisions take up to 15 calendar days. If your patient has significant functional impairment, falls, respiratory concerns, or rapidly worsening symptoms, explicitly request an expedited review in writing. Federal regulations require payers to issue expedited decisions within 72 hours when a standard timeline would seriously jeopardize the patient's health. Include a brief clinical urgency statement in your PA submission.
Step 6: Manage Reauthorization Proactively
Amifampridine PAs typically require annual renewal. Payers will require documentation of positive clinical response — improvement in dynamometry, Timed 25-Foot Walk Test, or Timed Up and Go Test. Build clinical response documentation into your routine LEMS follow-up appointments so that reauthorization submissions are straightforward. Track baseline and follow-up values using validated tools.
Found
Rate
on average
How medfinder Can Help Your Patients
When your patients are having trouble identifying which specific specialty pharmacy location can fill their prescription, medfinder for providers can help. medfinder calls pharmacies on the patient's behalf to determine which ones can fill the specific medication, then texts the results. This saves patients hours of frustrating phone calls and helps get their prescription moving quickly.
For more detail on the current access environment, see: Amifampridine Shortage: What Providers and Prescribers Need to Know in 2026.
Frequently Asked Questions
Firdapse must be dispensed through specialty pharmacies that are in-network with the patient's insurance. Major networks that carry it include CVS Specialty, Walgreens Specialty, Accredo (Express Scripts), Optum Specialty, and Biologics by McKesson. Catalyst Pathways (1-833-422-8259) will identify the correct in-network pharmacy for each patient.
The most commonly accepted ICD-10 codes for LEMS prior authorization are G70.80 (Other myasthenia gravis without acute exacerbation) or G70.89 (Other specified myoneural disorders). Some payers may accept G70.81 (myasthenia gravis with acute exacerbation) if the patient is acutely worse. Check with the specific insurer for their preferred code.
Most payers grant initial PA approval for 12 months (1 month = 30 days). Reauthorization also requires 12-month intervals and documentation of positive clinical response — typically improvement in dynamometry scores, Timed 25-Foot Walk Test, or Timed Up and Go Test. Track baseline values at initiation so reauthorization documentation is straightforward.
Catalyst Pathways is Catalyst Pharmaceuticals' free support program for Firdapse patients and their prescribers. For providers, it offers PA coordination, specialty pharmacy routing, enrollment forms, and appeals support. For patients, it provides copay assistance ($0/month for eligible commercially insured patients), bridge medication, and case management. Contact: 1-833-422-8259 or firdapse.com/support-and-savings/.
LEMS is a complex neuromuscular condition requiring specialist expertise for diagnosis and management. While telemedicine consultation is possible for established patients, initial prescribing typically requires in-person evaluation by a neurologist or neuromuscular specialist with access to EMG/NCS facilities. Some academic medical centers offer telemedicine neuromuscular consultations for established LEMS patients.
Medfinder Editorial Standards
Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.
Read our editorial standardsPatients searching for Amifampridine also looked for:
More about Amifampridine
39,483 have already found their meds with Medfinder.
Start your search today.
Your information is private and never shared.





